Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β 2-Adrenoceptor Agonist with Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular Safety Window in Preclinical Studies.

Koziczak-Holbro M, Rigel DF, Dumotier B, Sykes DA, Tsao J, Nguyen NH, Bösch J, Jourdain M, Flotte L, Adachi Y, Kiffe M, Azria M, Fairhurst RA, Charlton SJ, Richardson BP, Lach-Trifilieff E, Glass DJ, Ullrich T, Hatakeyama S.

J Pharmacol Exp Ther. 2019 May;369(2):188-199. doi: 10.1124/jpet.118.255307. Epub 2019 Feb 28.

PMID:
30819762
2.

Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.

Rizzoli R, Sigaud A, Azria M, Herrmann FR.

Osteoporos Int. 2015 Jan;26(1):383-93. doi: 10.1007/s00198-014-2937-5. Epub 2014 Oct 22.

PMID:
25566730
3.

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro.

Gschwind HP, Glaenzel U, Waldmeier F, Wirz B, Sabia HD, Picard F, Weiss HM, Choi L, Swart PJ, Vasudevan A, Azria M.

Eur J Pharm Sci. 2012 Aug 30;47(1):44-55. doi: 10.1016/j.ejps.2012.04.023. Epub 2012 May 8.

PMID:
22579664
4.

The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.

Hämmerle SP, Mindeholm L, Launonen A, Kiese B, Loeffler R, Harfst E, Azria M, Arnold M, John MR.

Bone. 2012 Apr;50(4):965-73. doi: 10.1016/j.bone.2012.01.009. Epub 2012 Jan 25.

PMID:
22289659
5.

A microarray analysis of full depth knee cartilage of ovariectomized rats.

Bay-Jensen AC, Nielsen RH, Segovia-Silvestre T, Azria M, Staedtler F, Letzkus M, Hartmann N, Brachat AH, Karsdal MA.

BMC Res Notes. 2011 Mar 15;4:63. doi: 10.1186/1756-0500-4-63.

6.

Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.

Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C.

J Clin Pharmacol. 2011 Apr;51(4):460-71. doi: 10.1177/0091270010372625. Epub 2010 Jul 21. Review.

PMID:
20660294
7.

Influence of food intake on the bioavailability and efficacy of oral calcitonin.

Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, Christiansen C.

Br J Clin Pharmacol. 2009 Apr;67(4):413-20. doi: 10.1111/j.1365-2125.2009.03371.x.

9.

Salmon calcitonin: a review of current and future therapeutic indications.

Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L.

Osteoporos Int. 2008 Apr;19(4):479-91. Epub 2007 Dec 11. Review.

PMID:
18071651
10.
11.

Rationale for the potential use of calcitonin in osteoarthritis.

Manicourt DH, Devogelaer JP, Azria M, Silverman S.

J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):285-93. Review.

12.

Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.

Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.

J Bone Miner Res. 2005 Sep;20(9):1548-61. Epub 2005 Apr 27.

13.

Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.

Bagger YZ, Tankó LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C.

Bone. 2005 Sep;37(3):425-30.

PMID:
16005273
14.

Osteoporosis management in day-to-day practice. The role of calcitonin.

Azria M.

J Musculoskelet Neuronal Interact. 2003 Sep;3(3):210-3. No abstract available.

15.

Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation.

Jiang Y, Zhao J, Geusens P, Liao EY, Adriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK.

J Bone Miner Res. 2005 Jan;20(1):125-30. Epub 2004 Oct 18.

16.

Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.

Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.

J Bone Miner Res. 2004 Sep;19(9):1531-8. Epub 2004 Jul 26.

17.

The analgesic role of calcitonin following osteoporotic fracture.

Silverman SL, Azria M.

Osteoporos Int. 2002 Nov;13(11):858-67. Review.

PMID:
12415432
18.

Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.

Buclin T, Cosma Rochat M, Burckhardt P, Azria M, Attinger M.

J Bone Miner Res. 2002 Aug;17(8):1478-85.

19.

Possible mechanisms of the analgesic action of calcitonin.

Azria M.

Bone. 2002 May;30(5 Suppl):80S-83S. Review.

PMID:
12008164
20.
21.

Friendship and social competence in a sample of preschool children attending Head Start.

Vaughn BE, Azria MR, Krzysik L, Caya LR, Bost KK, Newell W, Kazura KL.

Dev Psychol. 2000 May;36(3):326-38.

PMID:
10830977
22.

Effects of calcitonin on animal and in vitro models of skeletal metabolism.

Wallach S, Rousseau G, Martin L, Azria M.

Bone. 1999 Nov;25(5):509-16. Review.

PMID:
10574570
23.

Treatment with calcitonin for osteoporosis.

Azria M.

Ann Rheum Dis. 1997 Jul;56(7):440-1. No abstract available.

24.

The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.

Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG.

Calcif Tissue Int. 1996 Apr;58(4):216-20.

PMID:
8661950
25.

25 years of salmon calcitonin: from synthesis to therapeutic use.

Azria M, Copp DH, Zanelli JM.

Calcif Tissue Int. 1995 Dec;57(6):405-8. No abstract available.

PMID:
8581869
26.

Osteoporosis.

Azria M.

BMJ. 1995 Jul 22;311(6999):263. No abstract available.

27.

Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue.

Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, Nagant de Deuxchaisnes C.

Calcif Tissue Int. 1994 Jul;55(1):71-3. Erratum in: Calcif Tissue Int 1994 Oct;55(4):320.

PMID:
7922793
28.

Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies.

Azria M, Behhar C, Cooper S.

Calcif Tissue Int. 1993 Jan;52(1):16-20.

PMID:
8240482
29.
30.

Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.

Reginster JY, Azria M, Gaspar S, Bleicher M, Franchimont N, Behhar M, Albert A, Franchimont P.

Calcif Tissue Int. 1992 Jun;50(6):518-20.

PMID:
1525707
31.

Disposition of sandostatin, a new synthetic somatostatin analogue, in rats.

Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G.

Drug Metab Dispos. 1989 Nov-Dec;17(6):699-703.

PMID:
2575511
32.

The value of biomarkers in detecting alterations in bone metabolism.

Azria M.

Calcif Tissue Int. 1989 Jul;45(1):7-11. No abstract available.

PMID:
2788483
33.

The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burckhardt P.

Calcif Tissue Int. 1987 Nov;41(5):252-8.

PMID:
3121149
34.

Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.

Thiébaud D, Burckhardt P, Jaeger P, Azria M.

Am J Med. 1987 Apr;82(4):745-50.

PMID:
3565431
35.
36.

The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP).

Tippins JR, Morris HR, Panico M, Etienne T, Bevis P, Girgis S, MacIntyre I, Azria M, Attinger M.

Neuropeptides. 1984 Sep;4(5):425-34.

PMID:
6333647
37.

Quantitative cytochemical responses to exogenously administered calcitonins in rat kidney and bone cells.

Salmon DM, Azria M, Zanelli JM.

Mol Cell Endocrinol. 1983 Dec;33(2-3):293-304.

PMID:
6228449
38.

[Pharmacokinetics of dihydroergotamine in patients with chronic liver disease (author's transl)].

Labayle D, Chalas J, Lavène D, Humbert M, Azria M, Lindenbaum A, Chaput JC.

Gastroenterol Clin Biol. 1982 Feb;6(2):129-34. French. No abstract available.

PMID:
7060855
39.

Flow measurement of blood radioactivity in animals.

Simonnet F, Azria M, Bourdinaud M, Simonnet G.

J Pharmacol Methods. 1982 Jan;7(1):65-74.

PMID:
7070106
40.

[New method of biological assay of calcitonin using miniature swine].

Azria M, Kiger JL.

Therapie. 1974 Sep-Oct;29(5):753-66. French. No abstract available.

PMID:
4462226
42.

[Application of the comparative toxicological evaluation method with Chironom larvae to talcs containing hexachlorophene].

Kiger JL, Azria M.

Ann Pharm Fr. 1973 Jan;31(1):37-44. French. No abstract available.

PMID:
4756099
43.

[Value of miniature swine in biomedical research].

Azria M, Kiger JL.

Therapie. 1972 Jul-Aug;27(4):723-32. French. No abstract available.

PMID:
4628399
44.

[Study of the microbial contamination of pharmaceutical syrups].

Lambin S, Desvignes A, Kiger JL, Azria M.

Ann Pharm Fr. 1972 Mar;30(3):161-8. French. No abstract available.

PMID:
4626230
45.

[Use of a miniature swine in pharmacokinetics. Problems set by determinations in blood. Regular extracorporeal circulation technique].

Azria M, Kiger JL.

Therapie. 1969 Nov-Dec;24(6):1123-31. French. No abstract available.

PMID:
5367187
46.

[Practical method of toxicologic evaluation comparative by biological assay on larva of Chironoma].

Kiger JL, Azria M.

Ann Pharm Fr. 1968 Jul-Aug;26(7):541-8. French. No abstract available.

PMID:
5729716
47.

[Methods of control of the sterility of injectable ampoule solutions of small volume by means of filtrating membranes].

Kiger JL, Azria M.

Ann Pharm Fr. 1968 May;26(5):351-7. French. No abstract available.

PMID:
5708740

Supplemental Content

Support Center